At a glance
ClinicalIndex Comparison Record- ✓Age 65 years or older
- ✓Documented clinical cardiovascular or cerebrovascular disease due to atherosclerosis
- ✓Candidate for lipid-lowering therapy with no contraindication to fluvastatin, niacin, or aspirin
- ✓LDL cholesterol <150 mg/dL if untreated or <125 mg/dL on statin monotherapy
- ✕Ineligible for MRI due to pacemaker, metal implants, or ferromagnetic devices
- ✕Claustrophobia
- ✕Prior esophageal disease precluding trans-esophageal MRI
- ✕LDL-C >150 mg/dL untreated or requiring statin doses exceeding specified maximums (atorvastatin >20 mg, simvastatin >20 mg, fluvastatin >80 mg, pravastatin >80 mg, rosuvastatin >20 mg)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
HDL Increased Plaque Stabilization in the Elderly
In Brief
A Phase 3 clinical trial evaluating any statin, niacin, and 1 other intervention for Atherosclerosis and Cardiovascular Disease. Completed, enrolled 145 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate the added benefits of increased high-density lipoprotein (HDL) cholesterol serum levels over and above those achieved by lipid lowering therapy guided by current guidelines, in older individuals with cardiovascular disease.
Study Details
Timeline
Interventions
Participants will be provided a prescription for fluvastatin 80 mg to be taken on a daily basis, or they may continue their ongoing or any other cholesterol-lowering drugs such as pravastatin 80 mg daily, simvastatin 20 mg daily, atorvastatin up to 20 mg daily or rosuvastatin up to 20 mg daily for 18 months
long-acting niacin daily for 18 months
matching placebo pill daily for 18 months